Physician profile
Daniel Robert Pitts
NPI 1225491236
$2,358.33
in general payments reported to CMS, 2019-2025
20 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.94 · 2022: $613 · 2023: $910 · 2024: $364 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.22 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.57 | 2022-2025 | |
| Astellas Pharma US INC | $637.81 | 2021-2024 | Xtandi, Myrbetriq |
| Urogen Pharma, INC. | $209.68 | 2023-2025 | Jelmyto |
| Calyxo, INC. | $137.67 | 2025 | Cvac Aspiration System |
| Urovant Sciences INC | $87.92 | 2021-2022 | |
| Pfizer INC. | $83.64 | 2022 | |
| Endo Pharmaceuticals INC. | $82.81 | 2022-2023 | Xiaflex |
| Coloplast Corp | $75.36 | 2022 | |
| Axonics, INC. | $64.21 | 2021-2023 | Axonics |
| Merck Sharp & Dohme LLC | $50.59 | 2022-2024 | Keytruda |
| C. R. Bard, INC. & Subsidiaries | $47.87 | 2025 | Bard Urinary Drainage Bag |
| Sumitomo Pharma America, INC. | $33.92 | 2023 | Orgovyx |
| Myovant Sciences INC. | $32.38 | 2022 | |
| Janssen Biotech, INC. | $30.15 | 2021-2022 | |
| Boston Scientific Corporation | $25.86 | 2025 | Axonics |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24.67 | 2022 | |
| Tolmar, INC. | $22.58 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $21.41 | 2022 | |
| Convatec INC. | $19.63 | 2023 | |
| Ferring Pharmaceuticals INC. | $15.60 | 2024 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.